These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 28710315)

  • 21. Mutational spectrum of breast cancer by shallow whole-genome sequencing of cfDNA and tumor gene panel analysis.
    Ambriz-Barrera F; Rojas-Jiménez E; Díaz-Velásquez CE; De-La-Cruz-Montoya AH; Martínez-Gregorio H; Ruiz-De-La-Cruz M; Huertas A; Montealegre AL; Castro-Rojas C; Acosta G; Vaca-Paniagua F; Perdomo S
    PLoS One; 2024; 19(9):e0308176. PubMed ID: 39264897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
    Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
    Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
    Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
    Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
    [No Abstract]   [Full Text] [Related]  

  • 25. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
    Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
    Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
    Coco S; Theissen J; Scaruffi P; Stigliani S; Moretti S; Oberthuer A; Valdora F; Fischer M; Gallo F; Hero B; Bonassi S; Berthold F; Tonini GP
    Int J Cancer; 2012 Oct; 131(7):1591-600. PubMed ID: 22234802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations.
    Bouzidi A; Labreche K; Baron M; Veyri M; Denis JA; Touat M; Sanson M; Davi F; Guillerm E; Jouannet S; Charlotte F; Bielle F; Choquet S; Boëlle PY; Cadranel J; Leblond V; Autran B; Lacorte JM; Spano JP; Coulet F;
    Front Cell Dev Biol; 2021; 9():661272. PubMed ID: 34710202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-free DNA copy number variations in plasma from colorectal cancer patients.
    Li J; Dittmar RL; Xia S; Zhang H; Du M; Huang CC; Druliner BR; Boardman L; Wang L
    Mol Oncol; 2017 Aug; 11(8):1099-1111. PubMed ID: 28504856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells.
    Gao Y; Ni X; Guo H; Su Z; Ba Y; Tong Z; Guo Z; Yao X; Chen X; Yin J; Yan Z; Guo L; Liu Y; Bai F; Xie XS; Zhang N
    Genome Res; 2017 Aug; 27(8):1312-1322. PubMed ID: 28487279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
    Scaruffi P; Coco S; Cifuentes F; Albino D; Nair M; Defferrari R; Mazzocco K; Tonini GP
    Cancer Genet Cytogenet; 2007 Aug; 177(1):20-9. PubMed ID: 17693187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.
    Khalil AIS; Khyriem C; Chattopadhyay A; Sanyal A
    BMC Bioinformatics; 2020 Apr; 21(1):147. PubMed ID: 32299346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic profiling of cell-free DNA from dogs with benign and malignant tumors.
    Du H; Liu W; Li Y; Zhang L; Jiang F; Zhu D; Li J; Hu P; Yan N; Mao M; Li S
    BMC Res Notes; 2024 Sep; 17(1):264. PubMed ID: 39272211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
    Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
    Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic Copy Number Alteration in Circulating Tumor DNA for Monitoring of Pediatric Patients with Cancer.
    Ruas JS; Silva FLT; Euzébio MF; Biazon TO; Daiggi CMM; Nava D; Franco MT; Cardinalli IA; Cassone AE; Pereira LH; Seidinger AL; Maschietto M; Jotta PY
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.
    Przybyl J; Chabon JJ; Spans L; Ganjoo KN; Vennam S; Newman AM; Forgó E; Varma S; Zhu S; Debiec-Rychter M; Alizadeh AA; Diehn M; van de Rijn M
    Clin Cancer Res; 2018 Jun; 24(11):2688-2699. PubMed ID: 29463554
    [No Abstract]   [Full Text] [Related]  

  • 40. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients.
    Martignano F; Munagala U; Crucitta S; Mingrino A; Semeraro R; Del Re M; Petrini I; Magi A; Conticello SG
    Mol Cancer; 2021 Feb; 20(1):32. PubMed ID: 33579306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.